Printer Friendly

ROBERTS PHARMACEUTICAL AND BAYER AG COMPLETE LICENSING AGREEMENT FOR NEW ANALGESIC DRUG

 ROBERTS PHARMACEUTICAL AND BAYER AG COMPLETE LICENSING
 AGREEMENT FOR NEW ANALGESIC DRUG
 EATONTOWN, N.J., April 8 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced earlier today that it has signed an exclusive licensing agreement with Bayer AG of Leverkusen, Germany for worldwide rights to the analgesic drug, DIRAME (R) (propiram fumarate). The license granted to Roberts by Bayer is royalty bearing with Bayer retaining co-marketing rights under certain circumstances. DIRAME (R) is entering Phase III clinical trials in the United States this year. Overseas, Roberts plans to commence the submission of new drug applications within the EEC and Scandinavia.
 DIRAME (R) is a non-addicting analgesic for the relief of moderate to severe pain. Because of its pharmacologic properties, the drug is non-addictive and retains a potency equivalent to that of classic narcotic analgesics. DIRAME (R) is indicated for the management of cancer pain, traumatic and post-surgical pain and the pain associated with dental surgery and childbirth.
 Roberts CEO, Robert Vukovich noted, "DIRAME (R) is an important product for our company with broad market appeal. We expect to focus our promotional efforts on hospital sales and specialty use." He continued, "Our promotional efforts for DIRAME (R) will be synergistic with the promotion of several of our other products, especially those used for cancer therapy, such as SOMAGARD and AGRELIN."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non- prescription pharmaceuticals in the United States and abroad.
 -0- 4/8/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceutical, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation; Bayer AG ST: New Jersey IN: MTC SU: LIC


TQ-OS -- NY092 -- 6406 04/08/92 16:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 8, 1992
Words:313
Previous Article:AMERICA'S CUP COMPETITOR 'JAYHAWK' DISPLAYED AT CHEVROLET HEADQUARTERS; NEWS CONFERENCE TO BE HELD
Next Article:EPA TO HOLD PRESS BRIEFING ON APRIL 9 IN TEMPLE TERRACE, FLA., REGARDING CLEANUP ACTIVITIES AT THE NORMANDY PARK APARTMENTS


Related Articles
ROBERTS PHARMACEUTICAL ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO NEW ANALGESIC DRUG
STERLING WINTHROP WINS MAJOR VICTORY IN COURT BATTLE TO PROTECT BAYER NAME AND TRADEMARK IN THE UNITED STATES
STERLING WINTHROP INC. RESPONDS TO COURT DECISION ON BAYER(R) TRADEMARK
STERLING WINTHROP INC. RESPONDS TO COURT DECISION ON BAYER(R) TRADEMARK
PHARMACOPEIA AND BAYER ANNOUNCE RESEARCH COLLABORATION
PHARMACOPEIA AND BAYER ANNOUNCE RESEARCH COLLABORATION
CV THERAPEUTICS AND BAYER SIGN AGREEMENT TO DEVELOP NOVEL ANTI-INFLAMMATORY AGENTS
Bayer, Roche To Form OTC Joint Venture In The United States
Roberts Pharmaceutical Corporation Receives License from Wyeth Laboratories To Market Lodine in the U.K. and Ireland
Bayer AG Announces US$ 100 Million Alliance in Life Science Research.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters